Viral-mediated noisy gene expression reveals biphasic E2f1 response to MYC.

Gene expression mediated by viral vectors is subject to cell-to-cell variability, which limits the accuracy of gene delivery. When coupled with single-cell measurements, however, such variability provides an efficient means to quantify signaling dynamics in mammalian cells. Here, we illustrate the utility of this approach by mapping the E2f1 response to MYC, serum stimulation, or both. Our results revealed an underappreciated mode of gene regulation: E2f1 expression first increased, then decreased as MYC input increased. This biphasic pattern was also reflected in other nodes of the network, including the miR-17-92 microRNA cluster and p19Arf. A mathematical model of the network successfully predicted modulation of the biphasic E2F response by serum and a CDK inhibitor. In addition to demonstrating how noise can be exploited to probe signaling dynamics, our results reveal how coordination of the MYC/RB/E2F pathway enables dynamic discrimination of aberrant and normal levels of growth stimulation.

[1]  J L Cleveland,et al.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.

[2]  G. Evan,et al.  Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max , 1992, Nature.

[3]  J. Nevins,et al.  Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals , 1997, Molecular and cellular biology.

[4]  W. Sellers,et al.  Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. , 1998, Genes & development.

[5]  S. Lowe,et al.  Intrinsic tumour suppression , 2004, Nature.

[6]  H. Jäckle,et al.  Dimerization and the control of transcription by Krüppel , 1993, Nature.

[7]  Andrea Cocito,et al.  Genomic targets of the human c-Myc protein. , 2003, Genes & development.

[8]  S. Weintraub,et al.  Retinoblastoma protein switches the E2F site from positive to negative element , 1992, Nature.

[9]  M. Eilers,et al.  Transcriptional repression by Myc. , 2003, Trends in cell biology.

[10]  Seiichi Mori,et al.  An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. , 2008, Cancer cell.

[11]  Jehoshua Bruck,et al.  Regulatory modules that generate biphasic signal response in biological systems. , 2004, Systems biology.

[12]  J. Raser,et al.  Noise in Gene Expression: Origins, Consequences, and Control , 2005, Science.

[13]  Mina J. Bissell,et al.  Putting tumours in context , 2001, Nature Reviews Cancer.

[14]  T. Elston,et al.  Stochasticity in gene expression: from theories to phenotypes , 2005, Nature Reviews Genetics.

[15]  C. Conti,et al.  Inactivation of E2f1 enhances tumorigenesis in a Myc transgenic model. , 2002, Cancer research.

[16]  C. Dang,et al.  Induction of ribosomal genes and hepatocyte hypertrophy by adenovirus-mediated expression of c-Myc in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Giacomo Finocchiaro,et al.  Myc-binding-site recognition in the human genome is determined by chromatin context , 2006, Nature Cell Biology.

[18]  I. Bièche,et al.  Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. , 1999, Cancer research.

[19]  J. Nevins,et al.  Complex Transcriptional Regulatory Mechanisms Control Expression of the E2F3 Locus , 2000, Molecular and Cellular Biology.

[20]  G. Carmichael,et al.  An alternative pathway for gene regulation by Myc , 1997, The EMBO journal.

[21]  J. Nevins,et al.  A role for Myc in facilitating transcription activation by E2F1 , 2008, Oncogene.

[22]  Kathryn A. O’Donnell,et al.  The c-Myc target gene network. , 2006, Seminars in cancer biology.

[23]  Joseph R. Nevins,et al.  A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells , 2004, Nature Cell Biology.

[24]  A. Datta,et al.  ARF Directly Binds DP1: Interaction with DP1 Coincides with the G1 Arrest Function of ARF , 2005, Molecular and Cellular Biology.

[25]  Antoine Buetti-Dinh,et al.  Control and signal processing by transcriptional interference , 2009, Molecular systems biology.

[26]  Joseph B. Rayman,et al.  E 2 F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC 1 / mSin 3 B corepressor complex , 2002 .

[27]  Bruno Amati,et al.  Oncogenic activity of the c-Myc protein requires dimerization with Max , 1993, Cell.

[28]  J. Hasty,et al.  Dynamics of single-cell gene expression , 2006, Molecular systems biology.

[29]  R. Eisenman,et al.  Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. , 1991, Science.

[30]  J. Trent,et al.  Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc , 1984, Nature.

[31]  Y. Qi,et al.  p19ARF directly and differentially controls the functions of c-Myc independently of p53 , 2004, Nature.

[32]  W. El-Deiry,et al.  Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[33]  M. Cole,et al.  Mechanism of transcriptional activation by the Myc oncoproteins. , 2006, Seminars in cancer biology.

[34]  G. Prendergast,et al.  c‐Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. , 1994, The EMBO journal.

[35]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[36]  J. Mendell.  miRiad Roles for the miR-17-92 Cluster in Development and Disease , 2008, Cell.

[37]  Joseph B. Rayman,et al.  Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. , 2000, Genes & development.

[38]  Carla Grandori,et al.  c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I , 2005, Nature Cell Biology.

[39]  J. M. Thomson,et al.  Direct Regulation of an Oncogenic Micro-RNA Cluster by E2F Transcription Factors* , 2007, Journal of Biological Chemistry.

[40]  P. Leder.  Translocations among antibody genes in human cancer. , 2019, IARC scientific publications.

[41]  J. Nevins.  Definition and mapping of adenovirus 2 nuclear transcription. , 1980, Methods in enzymology.

[42]  Tae J. Lee,et al.  A bistable Rb–E2F switch underlies the restriction point , 2008, Nature Cell Biology.

[43]  Wen-Hwa Lee,et al.  Expression and amplification of the N-myc gene in primary retinoblastoma , 1984, Nature.

[44]  C. Croce,et al.  Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[45]  S. Deming,et al.  Cell cycle basis for the onset and progression of c-Myc-induced, TGFα-enhanced mouse mammary gland carcinogenesis , 2000, Oncogene.

[46]  W. Benedict,et al.  Erratum: Expression and amplification of the N-myc gene in primary retinoblastoma , 1984, Nature.

[47]  David M. Livingston,et al.  Functional interactions of the retinoblastoma protein with mammalian D-type cyclins , 1993, Cell.

[48]  R. Weinberg,et al.  Species- and cell type-specific requirements for cellular transformation. , 2004, Cancer cell.

[49]  S. Thorgeirsson,et al.  Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha. , 1998, Cancer research.

[50]  Joseph R. Nevins,et al.  Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F , 1997, Nature.

[51]  J. Nevins,et al.  The Rb/E2F pathway and cancer. , 2001, Human molecular genetics.

[52]  P. Liberali,et al.  Population context determines cell-to-cell variability in endocytosis and virus infection , 2009, Nature.

[53]  R. Sears,et al.  CIP2A Inhibits PP2A in Human Malignancies , 2007, Cell.

[54]  J. Nevins,et al.  Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. , 1994, Genes & development.

[55]  M E Greenberg,et al.  Myc requires distinct E2F activities to induce S phase and apoptosis. , 2001, Molecular cell.

[56]  Karen H. Vousden,et al.  p14ARF links the tumour suppressors RB and p53 , 1998, Nature.

[57]  A. Oudenaarden,et al.  Nature, Nurture, or Chance: Stochastic Gene Expression and Its Consequences , 2008, Cell.

[58]  S. Reed,et al.  The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2). , 2002, Genes & development.

[59]  Doron Betel,et al.  Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. , 2009, Genes & development.

[60]  G. Evan,et al.  The c‐Myc protein induces cell cycle progression and apoptosis through dimerization with Max. , 1993, The EMBO journal.

[61]  S. Lowe,et al.  miR-19 is a key oncogenic component of mir-17-92. , 2009, Genes & development.

[62]  Lars-Gunnar Larsson,et al.  c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription , 2005, Nature Cell Biology.

[63]  A Joly,et al.  CVT-313, a Specific and Potent Inhibitor of CDK2 That Prevents Neointimal Proliferation* , 1997, The Journal of Biological Chemistry.

[64]  G. Evan,et al.  c‐Myc‐induced apoptosis in fibroblasts is inhibited by specific cytokines. , 1994, The EMBO journal.

[65]  P. Fernandez,et al.  Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. , 2001, Genes & development.

[66]  R. Weinberg,et al.  Cellular oncogenes and multistep carcinogenesis. , 1983, Science.

[67]  A. Zetterberg,et al.  Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[68]  T. Volkert,et al.  E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. , 2002, Genes & development.

[69]  Kathryn A. O’Donnell,et al.  c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.

[70]  G. Evan,et al.  Distinct thresholds govern Myc's biological output in vivo. , 2008, Cancer cell.

[71]  W. Lim,et al.  Defining Network Topologies that Can Achieve Biochemical Adaptation , 2009, Cell.

[72]  B. Clurman,et al.  Werner syndrome protein limits MYC-induced cellular senescence. , 2003, Genes & development.

[73]  M. Pickering,et al.  miR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progression , 2009, Oncogene.

[74]  Kathryn A. O’Donnell,et al.  An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets , 2003, Genome Biology.

[75]  M. Roussel,et al.  Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. , 2003, Molecular cell.

[76]  R. Sears,et al.  The alternatively initiated c-Myc proteins differentially regulate transcription through a noncanonical DNA-binding site. , 1994, Genes & development.